

MK-8719

Chemical Properties


CAS No. : 1382799-40-7

Formula: C₉H₁₄F₂N₂O₃S

Molecular Weight: 268.28

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	MK-8719 is a highly potent and selective inhibitor of O-GlcNAcase (OGA) [hOGA], with a K _i value of 7.9 nM.
Targets(IC ₅₀)	Others
In vivo	MK-8719 has excellent intrinsic potency and selectivity, high CNS exposure, improved Papp, favorable metabolic stability, good pharmacokinetics, and robust pharmacodynamic response[1].

Solubility Information

Solubility	DMSO: 50 mg/mL (186.37 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.45 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.7274 mL	18.6372 mL	37.2745 mL
5 mM	0.7455 mL	3.7274 mL	7.4549 mL
10 mM	0.3727 mL	1.8637 mL	3.7274 mL
50 mM	0.0745 mL	0.3727 mL	0.7455 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Selnick HG, et al. Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. *J Med Chem.* 2019 Sep 29.

Wang N, Yu M, Fu Y, et al. Blocking ATM Attenuates SKOV3 Cell Proliferation and Migration by Disturbing OGT/OGA Expression via hsa-miR-542-5p. *Frontiers in Oncology.* 2022.12

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481